banner

On the road to discovery.... Diagnostics Development, Molecularly-Targeted Therapeutics

Cancer treatment is rapidly proceeding towards the era of personalized medicine where treatment is based on the distinctive molecular characteristics of a patient's tumor. This knowledge will allow patients to receive novel combinations of therapies that will maximize clinical benefit, more accurately predict disease outcome, and allow patients at the highest risk of relapse to receive the most aggressive treatment.

The Thoracic Oncology Lab is pursuing a variety of strategies to treat and cure lung cancer, mesothelioma and esophageal cancer. These include the investigation of molecular pathways such as Wnt and Hh, the role of inflammation in lung carcinogenesis, isolation of lung cancer stems cells, and the Lung Cancer Systems Genetics Project, An Approach to Individualized Lung Cancer Diagnosis and Therapy. Eventually, these efforts will have a major impact on these diseases.

DSC_0082 - Copy

Click to Enlarge

Recent Publications

Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer.
Cell reports, Apr-07-2015; 111: 98-110.  Epub 2015 Apr 2.
You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
Oncotarget, Jan-23-2015; [Epub ahead of print].
Letteboer TG, Benzinou M, Merrick CB, Quigley DA, Zhau K, Kim IJ, To MD, Jablons DM, van Amstel JK, Westermann CJ, Giraud S, Dupuis-Girod S, Lesca G, Berg JH, Balmain A, Akhurst RJ
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Frontiers in genetics, [epublish] 6: 67.
Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang L, Au A, Stoppler HJ, Xu Z, Jablons DM, You L
CK2¿, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
Journal of experimental & clinical cancer research : CR, Nov-25-2014; [Epub ahead of print] 331: 93.
Mo ML, Ma J, Chen Z, Wei B, Li H, Zhou Y, Shi H, Tolani B, Jin JQ, Tseng HH, Shen D, Zhan Y, Li J, Jablons DM, Zhang RQ, Guo Y, He B, Zhou HM
Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.
Journal of cancer research and clinical oncology, Nov-04-2014; [Epub ahead of print].
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ
Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer.
Clinical lung cancer, Nov-01-2014; 156: 426-32.  Epub 2014 Aug 15.
Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA
Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, Oct-07-2014; [Epub ahead of print].
Giroux Leprieur E, Hirata T, Mo M, Chen Z, Okamoto J, Clement G, Li H, Wislez M, Jablons DM, He B
The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Lung cancer (Amsterdam, Netherlands), Sep-01-2014; 853: 465-71.  Epub 2014 Jun 30.
Yang YL, Jablons D, You L
An alternative way to initiate Notch1 signaling in non-small cell lung cancer.
Translational lung cancer research, Aug-01-2014; 34: 238-41.
Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL
Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.
Science translational medicine, Jun-18-2014; 6241: 241ra79.
Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L
Lung tumourigenesis in a conditional Cul4A transgenic mouse model.
The Journal of pathology, Jun-01-2014; 2332: 113-23.
View all Publications »